Curacle Co., Ltd., a bio-venture business, engages in the research and development of drugs for diseases caused by aging process and damage to blood vessels. Its products cover age-related vascular diseases, intractable metabolic diseases, and cancer targeting/immunotherapy. The company’s products in pipeline include CU06, which covers treatment and medical indications, such as diabetic macular edema/retinopathy, acute respiratory distress syndrome, myocardial infarction, stroke treatment, concomitantly used with immunotherapy, inflammatory bowel disease treatment, and hereditary angioedema; CU03, which is in Phase 2a clinical trial study for the treatment of age-related macular degeneration; and CU01, a diabetic nephropathy medicine that completed Phase 2a clinical trial. Its products in back-up pipeline include CU02, a product for nonalcoholic steatohepatitis treatment; CU04, a product for the treatment of cancer (c-Myc inhibitor); and CU05, a product for the treatment of cancer (Amigo2-PDK1 inhibitor). The company was founded in 2016 and is based in Seoul, South Korea.
Metrics to compare | 365270 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship365270PeersSector | |
---|---|---|---|---|
P/E Ratio | −3.1x | −4.4x | −0.6x | |
PEG Ratio | 0.17 | −0.09 | 0.00 | |
Price/Book | 2.8x | 2.5x | 2.6x | |
Price / LTM Sales | 51.1x | 5.7x | 3.3x | |
Upside (Analyst Target) | - | 0.0% | 37.8% | |
Fair Value Upside | Unlock | 12.2% | 4.3% | Unlock |